Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDA Treatment Option for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Dr. Christopher J. Hoimes, Associate Professor of Medicine-GU Oncology at Duke University, presents data on the KEYNOTE-045 Phase 3 Trial, which demonstrated that patients treated with KEYTRUDA (pembrolizumab) had a 27% reduction in risk of death compared to patients treated with chemotherapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form